Cancer is a highly complex disease caused by a set of oncogenic protein-coding genes and non-coding genes, and, thus, targeted analyses of these genes through highly innovative technologies are the best methods for cancer diagnosis, prognosis, risk assessment and treatment follow-up of various cancers. These are the most powerful research technologies that can save the lives of millions of cancer patients.
At GeneVerify, Inc., we have assembled a highly talented, multi-disciplinary team of molecular biologists, cell biologists, pathologists, biochemists, urologists, surgical oncologists, medical oncologists, radiation oncologists, physicians and surgeons committed every day to meeting the challenges of evolving gene-based diagnosis and treatment of various solid tumors.
GeneVerify, Inc., is developing in vitro diagnostic (IVD) reagents for laboratory- based assays for analysis of a set of oncogenic genes in various cancers using real-time PCR technology. We are also developing novel technologies to target these genes that will provide the most effective and highly specific treatment for various cancers.
(Protein coding genes and Non-coding genes analyses)
Analyses of a set of oncogenic protein coding genes and non-coding genes for in vitro diagnostic assays in research laboratory only. Analyses must be corelated by surgical oncologists/ medical oncologists/ radiation oncologists / pathologists/ physicians/ surgeons/ for diagnosis, prognosis, risk assessment and monitoring therapies of various cancers
In Vitro Diagnostic Reagents (Research and Development)
Targeting Oncogenic Protein coding genes and non-coding genes for treatment. Pre- IND (Investigational New Drug)
Genes based therapies that target oncogenes that are involved in cancer initiation, progression and metastasis.
Research and Development
Pre-IND (Investigational New Drug
Phase-1 Phase-2 Phase-3
“Precision Medicine” is a relatively new approach for disease treatment that takes into account, among other things, individual variability of genes. The precision medicine approach is based on genetic profiling of a set of tumors. Based on published literature, one in five patients that are newly diagnosed with cancer has a different combination of genetic changes and gene profiling, and, thus, one drug does not fit all with less consideration of the genetic differences between individuals. Therefore, each patient’s tumor has unique, individualized, genetic abnormalities, such as mutation, re-arrangement, translocation, polymorphic variants, gene fusions, gene amplification, gene deletion, abnormalities in microRNAs (miRNAs) and long-non-coding RNAs (lncRNAs), and DNA methylation.
In precision medicine, we must utilize the latest technologies for tumor genomics through multi-omics, such as genome, proteome, transcriptome, epigenome, metabolome, and microbiome profiling. Based on the Human Genome Project data analyses, there are more than 30,000 protein-coding genes and 60,000 non-coding genes.
Our professionals have dedicated their careers addressing cancer genetics and epigenetics for over 40 years and published more than 550 peer-reviewed research papers in high impact journals.
According to the NIH RePORTER database, our laboratory has been awarded / funded research projects 99 times through the NCI/NIH and U.S. Department of Veterans Affairs. We have several US patents in the field of urology and oncology resulting from major NCI/NIH funding initiatives.
At GeneVerify, Inc., we are developing in vitro diagnostic reagents for research laboratory- based assays for analysis of a set of oncogenes in various cancers using real-time PCR technology. We are also developing novel medical technologies to target these oncogenes that will provide the most effective and highly specific treatment for various cancers. These are the most powerful research and innovative technologies that can save the lives of millions of cancer patients.
According to the Cancer Statistics of 2024, approximately 20 million people worldwide are newly diagnosed with cancer each year. By 2030, this number is projected to double if not properly controlled. A significant issue is the lack of testing for early diagnosis, prognosis, and treatment follow-up. In some Southeast Asian countries, such as India, around 40% of cancer patients are diagnosed at a metastatic stage due to inadequate testing. Nearly all cancer-related deaths are caused by metastasis, and currently, there is no effective therapy for metastatic cancer.
At GeneVerify, Inc., our professionals believe that early identification and intervention, specifically targeting a set of oncogenes, can inhibit cancer progression and metastasis. These cutting-edge technologies will improve patient outcomes while simultaneously reducing healthcare costs.
We have developed a novel blood-based mRNA genomic technology, which holds 5 U.S. patents and has been featured in over 200 original research publications in high-impact journals.
Our blood-based mRNA genomic technology can be utilized for screening, early diagnosis, prognosis, treatment follow-up, and gene therapy for various cancers. These tests have undergone 9 clinical trials across 9 hospitals in the USA, Japan, and India, demonstrating 95% specificity and sensitivity.
Our team consists of more than 50 medical scientists with expertise in medical oncology, surgical oncology, pathology, radiation oncology, molecular biology, genetics, gene therapy, cancer biology, and biochemistry, who have been working in the USA for the past 20 to 40 years.
On January 25-27th, 2024, we presented our data at the ASCO GU symposium (American Society of Clinical Oncology) meeting at San Francisco, California, USA. ASCO has 45,000 members worldwide. This paper was published in the Journal of Clinical Oncology January 29th 2024.
https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.271
On April 5-10, 2024, we presented our data at the AACR meeting (American Association of Cancer Research) at San Diego, CA. AACR has 58,000 members from 141 countries (google search). This paper was published in the Journal “CANCER RESEARCH” March 22, 2024.
On May 3-6, 2024 we presented our data at AUA (American Urology Association) at San Antonio, Texas. AUA has more than 25,000 members from 138 counties (google search). This paper was published in the Journal “Journal of Urology” May, 2024.
https://www.auajournals.org/doi/10.1097/01.JU.0001008896.93851.5b.05
It has following advantages:
GeneVerify’s targeted genetic testing kits are the path to value-based rapid testing, discovery and identification, and risk prediction that is invaluable to early intervention.
Backed by our genetic testing profiling, medical oncologists and surgical oncologists may enable to (i) diagnose early stage cancer (ii) predict whether tumor is aggressive or slow growing and thus provide better decisions for surgery or active surveillance (iii) predict prognosis and risk assessment of cancer based on genetic profiling (iv) better predict how a patient might respond to certain modalities and therapies more accurately, and (v) achieve a solid basis for better decision-making on a patient’s therapeutic treatment and future evaluation to yield the quickest results, thereby enhancing your patient’s health, lengthen life, and reduce illness and disability.
At GeneVerify, Inc., we are tackling the issues that matter most to patient care in a collaborative setting where teamwork and innovation leads to more answers.
Founder, CEO and President
Chief Scientific Officer
Scientific Adviser
Vice-President
Kulkarni P, Dasgupta P, Hashimoto Y, Shiina M, Shahryari V, Tabatabai ZL, Yamamura S, Tanaka Y, Saini S, Dahiya R, Majid
Cancer Res. 2021 Mar 15;81(6):1500-1512. doi: 10.1158/0008-5472.CAN-20-0832. Epub 2021 Jan 26.PMID: 33500248.
Dasgupta P, Kulkarni P, Majid S, Hashimoto Y, Shiina M, Shahryari V, Bhat NS, Tabatabai L, Yamamura S, Saini S, Tanaka Y, Dahiya R.
Cell Death Dis. 2020 Aug 19;11(8):660. doi: 10.1038/s41419-020-02877-0.PMID: 32814766 Free PMC article.
Bhagirath D, Liston M, Patel N, Akoto T, Lui B, Yang TL, To DM, Majid S, Dahiya R, Tabatabai ZL, Saini S.
Oncogene. 2020 Dec;39(49):7209-7223. doi: 10.1038/s41388-020-01493-8. Epub 2020 Oct 9.PMID: 33037409 Free PMC article.
3517 Breakwater Ave
Hayward, CA 94545
© 2024 GeneVerify Inc.